cabozantinib,atezolizumab
exelixis,roche
['urothelial carcinoma', 'urothelial', 'cosmic-021']
dr. updates the cosmic-021 trial with atezo-cabo in urothelial carcinoma, cohorts 3, 4 and 5. main benefit seem in 1st line patients (cohort 3 and 4), although 61% of ici pre-treated patients had disease control. #asco22 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer